CCA
CMPX icon

Cygnus Capital Advisors’s Compass Therapeutics CMPX Stock Holding History

Cygnus Capital Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,000
Closed -$95K – 79
2026
Q1 		$95K Buy
18,000
+8,000
+80% +$46.2K 0.06% 62
2025
Q4 		$54K Buy
+10,000
New +$46.2K 0.04% 67

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Cygnus Capital Advisors's CMPX Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 18,000 shares — an estimated $95K sold.

Cygnus Capital Advisors first reported a position in CMPX in Q4 2025 and held it in 2 quarters. The position peaked at $95K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 18,000 Compass Therapeutics shares in Q2 2026, an estimated $95K.
  • Cygnus Capital Advisors first reported a position in Compass Therapeutics in Q4 2025 and held it in 2 quarters.
  • Cygnus Capital Advisors's Compass Therapeutics position peaked at $95K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.